Daniel Allen Gold Sells 375,784 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 375,784 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $26.50, for a total transaction of $9,958,276.00. Following the completion of the transaction, the director owned 15,127,329 shares of the company’s stock, valued at approximately $400,874,218.50. The trade was a 2.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Daniel Allen Gold also recently made the following trade(s):

• On Wednesday, February 11th, Daniel Allen Gold sold 425,000 shares of Roivant Sciences stock. The shares were sold at an average price of $26.67, for a total value of $11,334,750.00.
• On Wednesday, December 17th, Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock. The stock was sold at an average price of $23.07, for a total value of $17,933,049.24.
• On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The shares were sold at an average price of $23.04, for a total value of $21,134,177.28.
• On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $26.45 on Friday. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $27.94. The stock has a 50-day moving average of $22.71 and a 200 day moving average of $18.36. The company has a market capitalization of $18.40 billion, a price-to-earnings ratio of -22.61 and a beta of 1.22.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. Leerink Partners raised their price target on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Guggenheim lifted their price objective on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 target price on shares of Roivant Sciences in a report on Monday, February 9th. Finally, Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.69.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jones Financial Companies Lllp grew its holdings in Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares during the period. SBI Securities Co. Ltd. lifted its position in shares of Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares in the last quarter. Allworth Financial LP lifted its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. Finally, CWM LLC increased its holdings in Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after acquiring an additional 920 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Multiple analysts raised price targets and maintained bullish ratings (HC Wainwright, Goldman Sachs, Leerink, Citi — consensus PT ~ $28.69), supporting a positive headline narrative for the stock. MarketBeat ROIV coverage
• Positive Sentiment: Institutional flows show new and increased positions (several funds added ROIV, LPL Financial materially increased its stake), which can provide demand support below recent highs. MarketBeat institutional ownership report
• Neutral Sentiment: HC Wainwright slightly improved its FY2026 EPS view (less negative) and kept a Buy rating with a $33 target — this is mixed for stock moves because estimates remain negative even as the price target was raised. HC Wainwright note
• Negative Sentiment: Director Daniel Allen Gold sold two large blocks (425,000 shares on Feb 11 and 375,784 shares on Feb 13) at ~ $26.50 per share (SEC filing). Large director sales can create near‑term selling pressure and raise investor caution. SEC filing — Daniel Gold sales
• Negative Sentiment: Insider Mayukh Sukhatme sold 339,441 shares on Feb 9 at ~$26.47; this is another sizable insider disposition following previous large sales, which may weigh on sentiment. InsiderTrades / sale report
• Negative Sentiment: HC Wainwright cut several 2027 quarterly EPS forecasts and lowered FY2027 EPS materially (from about -$1.22 to -$1.79), signaling expectations for weaker near‑term financial performance — a clear negative for sentiment until operational catalysts emerge. HC Wainwright estimate update

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.